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OBJECTIVES The present study aims to investigate whether laser Doppler flowmetry can be used to
monitor improvements in vascular function during statin therapy.
BACKGROUND Endothelial dysfunction is an early feature of atherosclerosis in hypercholesterolemic patients
and can be improved by statins. There are several methods to assess endothelial function in
vivo, none of them being feasible in everyday practice.
METHODS Skin perfusion, measured by laser Doppler flowmetry, was assessed at rest and during reactive
hyperemia. Nineteen hypercholesterolemic patients (age 42 to 73 years, total cholesterol 5.4
to 9.6 mmol/l) were studied before and during statin therapy. To further investigate the
mechanisms, postischemic skin hyperemia was measured before and after intradermal
injection of the nitric oxide synthase inhibitor L-NAME and its inactive isoform D-NAME
(0.5 mol/10 l each). On a separate day, the healthy volunteers were reexamined before and
2 h after 1,000 mg aspirin.
RESULTS Postischemic skin blood flow was markedly reduced in hypercholesterolemic patients (45 
11%) compared with healthy controls (238  20%, p  0.0001) and improved after statin
therapy (113 15%, p 0.0005 vs. pre-treatment). In the healthy volunteers, the hyperemic
responses were not significantly different after L-NAME and D-NAME. Aspirin reduced
hyperemia from 274  49% to 197  40% (p  0.025).
CONCLUSIONS Reactive hyperemia of the skin microcirculation can be easily and reproducibly assessed by
laser Doppler flowmetry. Vasodilator prostaglandins are the major mediators of postischemic
skin hyperemia, which is impaired in hypercholesterolemic patients and can be enhanced by
cholesterol-lowering therapy. Thus, laser Doppler flowmetry may represent a tool to assess
and monitor vascular function during therapy in everyday practice. (J Am Coll Cardiol
2003;42:71–7) © 2003 by the American College of Cardiology Foundation
Hypercholesterolemia is an important cardiovascular risk
factor (1–3), and lipid-lowering therapy with statins reduces
morbidity and mortality in the primary and secondary
prevention of cardiovascular disease (4–8). Hypercholester-
olemia is associated with reduced endothelium-dependent
responses in the forearm and coronary circulation (9–11).
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These changes can, in part, be normalized by statins (12,13).
The mechanisms by which statins improve endothelium-
dependent vasodilation are not completely understood, but
increasing evidence suggests that, besides the lipid lowering
properties of statins, direct vascular effects are also respon-
sible for the reduction of morbidity and mortality.
Nitric oxide (NO) and prostacyclin (PGI2), synthesized
and released by the vascular endothelium, play an important
role in the control of the vascular tone and structure
(14–16); NO is produced by the enzymatic conversion of
L-arginine to L-citrulline by NO synthase and possesses
vasodilating, antithrombotic, and anti-proliferative proper-
ties (17); PGI2, with similar biological characteristics, is
synthesized by cyclooxygenase from arachidonic acid (18).
Both mediators are released from endothelial cells in re-
sponse to shear stress during increased blood flow (19–22).
Atherosclerotic changes in blood vessels are thought to be
partly due to endothelial dysfunction with an imbalance
between endothelium-derived vasodilators and vasocon-
strictors (23).
Reactive hyperemia is a reflection of an increased require-
ment of blood flow after temporary occlusion of arterial
blood supply and is a result of myogenic and several
metabolic factors, for example, adenosine, ATP-sensitive
potassium channels, pH, pO2, prostaglandins, and NO
(24–30). Previous clinical studies investigated reactive hy-
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peremia mainly by means of ultrasonography or venous
occlusion plethysmography in the forearm (28,31,32). It has
been shown that the skin blood flow correlates poorly with
large vessel blood flow (blood flow mainly to the underlying
muscle), but that it reflects the endothelium-dependent
regulation of small skin vessels and is correlated to other
established methods to test endothelial function such as
plethysmography and laser-Doppler flowmeter (33–35).
Reactive hyperemia measured in the radial artery after
proximal limb occlusion is reduced in hypercholesterolemic
patients (36) and improved by lipid-lowering therapy. The
contribution of NO and PGI2 and the influence of statins to
reactive hyperemia of the skin has not been investigated yet.
In the clinical setting, the skin circulation has the advantage
that it is easily accessible also in everyday practice and,
hence, is an excellent candidate as a surrogate circulation for
clinical monitoring.
The objective of this study was to investigate the value of
laser Doppler flowmetry for the assessment of vascular
function as an easily practicable surrogate of existing tech-
niques.
METHODS
Measurement of skin blood flow. A laser Doppler flow-
meter (PF 3, Perimed, Sweden) with a probe holder was
used to assess skin blood flow. This method has been
previously described and validated. Red laser light is guided
to the skin through fiberoptics. There it is partly absorbed,
partly reflected, and recorded by a second fiberoptic bundle.
Circulating red cells cause a Doppler shift, whereas tissue
does not. The signal intensity, thus, depends on velocity and
the concentration of red cells. The sample volume approx-
imates 1 mm2. Absolute blood flow depends on the sample
volume, and, because the sample volume is not constant,
absolute blood flow cannot be calculated. The system gives
arbitrary perfusion units (37). The laser probe was placed
close to the wrist, distal from a blood pressure cuff loosely
placed around the arm. Skin temperature was measured next
to the probe in nine subjects. Stable baseline conditions
were recorded for 5 min. Then the cuff was inflated to
suprasystolic pressure for 4.5 min. After release of the cuff,
skin reactive hyperemia was recorded. The signal was
digitally recorded (Centris, Apple Computer, Cupertino,
California) using a modified commercial data acquisition
software (LabView, National Instruments, Austin, Texas)
and an analog/digital board (National Instruments). Be-
cause basal as well as peak skin blood considerably depends
on the precise location of the measurement, flow was
normalized to baseline and expressed as percent increase.
Pilot experiments revealed that the mean flow between 30
and 60 s after cuff deflation discriminated best between
before and during statin treatment (data not shown).
Experimental protocols. All experiments were performed
in a quiet, air-conditioned room with room temperature of
22°C to avoid changes in skin blood flow induced by
different ambient temperatures. Measurements were started
after a period of 20 min. All participants gave informed
consent, and the study was approved by the local ethics
committee.
Effects of statin therapy. A total of 19 hypercholester-
olemic patients (age 42 to 73 years; 2 female, 17 males; total
cholesterol, 5.4 to 9.6 mmol/l) were studied before and
during therapy with atorvastatin (n  8), simvastatin (n 
4), cerivastatin (n 6), or pravastatin (n 1). Concomitant
medication consisted of acetyl salicylic acid (100 mg daily,
n 11), beta-blockers (n 9), calcium antagonists (n 3),
vasodilators (n  1), anticoagulants (n  2), angiotensin-
converting enzyme inhibitors (n  4), diuretics (n  5),
digoxin (n  1), or amiodarone (n  1) and was not altered
during the study. The control group consisted of 12 young,
healthy nonsmokers, age 28  1 year, five females, seven
males.
Correlation between plasma lipid levels and skin reactive
hyperemia. Sixteen healthy normo- or hypercholester-
olemic volunteers (age, 31 to 70 years) with a wide range of
plasma cholesterol levels (low-density lipoprotein [LDL]
cholesterol, 1.8 to 9.6 mmol/l; high-density lipoprotein
[HDL] cholesterol, 0.9 to 2.5 mmol/l) were additionally
studied to investigate a possible correlation between plasma
lipid levels and skin reactive hyperemia (all without any
medication and all normotensive nonsmokers).
Study of the mechanisms of skin reactive hyperemia. In
six healthy normotensive subjects (age, 26 to 40 years; 3
males, 3 females), the mechanisms of skin reactive hyper-
emia as measured by laser Doppler flowmetry were investi-
gated. The NO synthase inhibitor N-omega-nitro-L-
arginine methyl ester (L-NAME) and its inactive isoform
D-NAME (Clinalfa, La¨ufelfingen, Switzerland) were in-
jected strictly intradermally into the left and right forearm
skin (solutions of 0.5·106 mol, injection volume 10 l
each), respectively, through 30G needles (Omnican, Braun,
Melsungen, Germany), as described previously by our group
(38,39). If there was visible spreading outside the produced
wheal, the injection site was excluded. After a resting period
of 40 min, the laser Doppler probe was placed on the center
of the flare, 4 to 5 mm from the injection site. After
recording of a stable baseline, arterial blood flow was
occluded for 4.5 min. After release of the arterial occlusion,
reactive hyperemia was recorded.
On a separate day, the effects of acetylsalicylic acid
(aspirin, 1 g orally; Aspirin, Bayer AG, Leverkusen, Ger-
many) was studied. Before and 2 h after oral administration
Abbreviations and Acronyms
D-NAME  N-omega-nitro-D-arginine methyl ester
HDL  high-density lipoprotein
LDL  low-density lipoprotein
L-NAME  N-omega-nitro-L-arginine methyl ester
NO  nitric oxide
PGI2  prostacyclin
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of the drug, skin reactive hyperemia was measured as
described.
Reproducibility of the method. To test the reproducibility
of the method, hyperemia was measured in six healthy
volunteers again after 13  5 weeks, under the same
conditions.
Statistical analysis. All results are presented as means 
SEM. The effects of the drugs were evaluated with paired
Student t test; intergroup differences were evaluated by
unpaired t tests (StatView 4.5, Abacus Concepts, Berkeley,
California [38]). A value of p  0.05 was considered
statistically significant.
RESULTS
Skin reactive hyperemia and plasma cholesterol levels.
There was a significant inverse association between LDL
and postischemic skin blood flow (Fig. 1) (r  0.62, p 
0.01). Total cholesterol plasma levels, but not triglycerides,
were also significantly correlated to postischemic skin blood
flow (r  0.52, p  0.029).
Skin reactive hyperemia and statins. Patients were exam-
ined before and after a mean of 6  0.8 weeks of
lipid-lowering therapy. Total cholesterol was reduced from
7.1  0.4 to 4.8  0.3 mmol/l (p  0.0001). Hyperemic
blood flow was markedly impaired in patients with hyper-
cholesterinemia (45 11%) compared with healthy controls
(238  20%, p  0.0001). Hyperemic skin blood flow
increased from 45  11% to 113  15% of baseline during
statin therapy (p  0.0005). Total cholesterol was lowered
by 33% as expected (n  11) (Figs. 2 and 3). Skin
temperature was comparable before and during statin ther-
apy (31.8  0.4°C and 32.2  0.4°C, p  NS, n  9).
Mechanisms of skin reactive hyperemia. Hyperemic
blood flow after oral administration of 1,000 mg aspirin was
blunted (197  40% vs. 274  49%, p  0.025) (Fig. 4A).
The hyperemic response was not significantly different
after intradermal injection of the NO synthase inhibitor
L-NAME (238 37%) and its inactive isoform D-NAME
(192  49%, respectively) (p  0.32) (Fig. 4B).
Reproducibility. Postischemic hyperemia was tested again
after 13 5 weeks in six of the healthy controls and proofed
to be comparable (243  36% and 229  32%, p  NS).
The control measurement was 4% lower (range, 17% to
36%). The coefficient of variation was 21%.
DISCUSSION
This study shows that, in patients with hypercholesterol-
emia, postischemic skin blood flow is correlated to plasma
cholesterol levels and that lipid-lowering therapy with
statins markedly increases the postischemic flow response as
measured by laser Doppler flowmetry. Vasodilator prosta-
glandins are the major physiologic mediators of postisch-
emic skin hyperemia, which is impaired in hypercholester-
olemic patients and enhanced by cholesterol-lowering
therapy.
Reactive hyperemia, cholesterol, and statins. Plasma
cholesterol levels correlate with morbidity and mortality
(1–3). The present study found an association between skin
reactive hyperemia and plasma cholesterol levels. Statins are
beneficial in the secondary prevention of cardiovascular
events (4–8). This appears only in part to be due to their
lipid-lowering property; indeed, the evidence is growing
that statins also influence the formation of endothelial
mediators (13,40). The present results show that the
marked increase of skin blood flow during statin therapy is
presumably due to increased bioavailability of vasodilator
prostaglandins. Skin temperature might influence post-
ischemic skin blood flow. However, this was monitored
closely in our study and cannot explain the improvement of
reactive hyperemia. Furthermore, the changes observed
were very marked and consistent; indeed, there was not a
single patient whose flow decreased during statin therapy.
Figure 1. Relation between maximal blood flow during reactive hyperemia
of the skin and plasma levels of low-density lipoprotein (LDL) cholesterol.
There was a significant inverse correlation between skin blood flow and
LDL cholesterol.
Figure 2. Skin blood flow during reactive hyperemia in normocholester-
olemic and hypercholesterolemic subjects and before and during therapy
with a statin (changes normalized to baseline flow). Hyperemic skin blood
flow in hypercholesterolemic patients is reduced compared with healthy
controls, *p  0.0001 versus healthy volunteers and can markedly be
increased by statin therapy, †p  0.0005 versus before treatment.
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Reactive hyperemia and prostaglandins. Reactive hyper-
emia denotes increased blood flow after temporary occlusion
of arterial blood flow and is a result of myogenic and several
metabolic factors, for example, adenosine, ATP-sensitive
potassium channels, pH, pO2, prostaglandins, and NO
(25–30,41); PGI2, a vasodilator prostaglandin produced
from arachidonic acid by constitutive cyclooxygenase in
endothelial cells, is mainly released in response to shear-
stress (22,42,43). The present results demonstrate that
vasodilator prostaglandins—most probably PGI2—are es-
sential mediators of reactive hyperemia in the human skin.
The release of vasodilator prostaglandins is likely to be a
result of increased shear stress generated by increased blood
flow during reactive hyperemia. In addition, our findings
show that prostaglandins contribute to the maintenance of
basal skin blood flow. This does not invalidate the clinical
use of aspirin because the low doses inhibit platelets but
have minimal effects on prostacyclin and is in line with
previous studies investigating the effects of prostaglandins
on skin blood flow (44–48).
Reactive hyperemia and NO. Nitric oxide is synthesized
by the vascular endothelium by the enzymatic conversion of
L-arginine to L-citrulline by NO synthase, which can be
inhibited by L-NAME (17). A major stimulus for NO
release is shear stress (19–22); NO plays an essential role in
the control of vascular tone and structure and exerts vaso-
dilating, anti-thrombotic, and antiproliferative properties
(23).
It has been demonstrated that NO importantly contrib-
utes to flow-mediated dilation of large human arteries
(28,31). In contrast, the present results exclude a major role
of NO in reactive hyperemia of the skin microcirculation,
because skin reactive hyperemia could not be inhibited by
pharmacologic inhibition of NO synthase. Similarly, others
found that dermal vasodilation in response to acetylcholine
is mediated predominantly by prostanoids rather than NO
(49). However, NO did contribute to basal skin blood flow
in our subjects, as also shown by previous studies (50,51).
Relevance of the study. Laser Doppler measurement of
skin reactive hyperemia could potentially represent a simple,
noninvasive method to study flow-mediated release of
endothelial mediators in patients with cardiovascular dis-
ease. Even before morphologic evidence of atherosclerotic
changes in the vessel wall, endothelial dysfunction can
evolve in response to injury by cardiovascular risk factors
(e.g., diabetes mellitus) (52), leading to impaired flow-
dependent vasodilation (36,53–56). Impaired flow-
mediated arterial dilation has also been demonstrated in a
number of disease states, for example, coronary artery
disease and congestive heart failure (57,58). In fact, a lower
peak blood flow during skin reactive hyperemia has been
found in diabetic patients compared with controls (59). In
contrast, arterial hypertension (which also causes endothe-
lial dysfunction) (60) does not seem to be associated with
altered skin reactive hyperemia (59,61).
Statin therapy has been shown to improve endothelial
function, as assessed by acetylcholine infusion to the coro-
nary and forearm circulation (12,13,62). Because the vaso-
dilator effects of acetylcholine in the skin are mediated
rather by vasodilator prostaglandins than NO (49) and skin
reactive hyperemia largely depends on vasodilator prosta-
glandins as shown in the present study, laser Doppler
Figure 3. Scattergram: individual patients undergoing cholesterol lowering. Total cholesterol was reduced by statins in every patient and postischemic blood
flow increased in every patient.
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flowmetry of the skin may serve as a simple, noninvasive
tool to assess endothelial function in daily practice.
Study limitations. The present study is limited by the fact
that it is not randomized and placebo-controlled. However,
the observed differences were large, and the reproducibility
of the method as shown in this study is acceptable. The
present study is descriptive, and no data can be given on a
possible relationship between these findings and prognosis
yet. A further limitation is that intracutaneous injection
leads to a small trauma and subsequent release of vasoactive
substances (e.g., potassium, bradykinin, and substance P).
These mediators may influence skin blood flow and could
confound the hyperemic response. However, by injecting
D-NAME—the inactive isoform of the NO synthase in-
hibitor L-NAME—as a control, we have tried to eliminate
these factors as much as possible. Another limiting factor is
the regulation of skin blood flow by systems other than the
endothelium, for example, the sympathetic nervous system
(63). By performing the experiments in an air-conditioned
and quiet room, confounding influences, for example, noise
and changing temperature, have been minimized.
Conclusions. Assessment of skin reactive hyperemia by
laser Doppler flowmetry is an easy and reproducible method
to assess and monitor vascular function. Vasodilator pros-
taglandins are the major mediators of postischemic skin
hyperemia, which is impaired in hypercholesterolemic pa-
tients and can be enhanced by cholesterol-lowering therapy.
Because laser Doppler flowmetry is a simple noninvasive
method for measuring skin blood flow during reactive
hyperemia, it may be clinically used to test and monitor
vascular function in patients before and during therapeutic
interventions.
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